Search Result

Results for "

Constipation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (12) Angiotensin-converting Enzyme (ACE) (2) Apical Sodium-Dependent Bile Acid Transporter (4) Apoptosis (3) Autophagy (3) Bacterial (3) Calcium Channel (1) Chloride Channel (3) Endogenous Metabolite (1) GHSR (1) GLUT (1) Guanylate Cyclase (7) Interleukin Related (3) Isotope-Labeled Compounds (1) mAChR (2) Motilin Receptor (1) Opioid Receptor (8) SARS-CoV (2) SGLT (2) TNF Receptor (3) TRP Channel (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (1) Endocrinology (3) Infection (2) Inflammation/Immunology (8) Metabolic Disease (21) Neurological Disease (18)

By Targets:

5-HT Receptor (12)

Angiotensin-converting Enzyme (ACE) (2)

Apical Sodium-Dependent Bile Acid Transporter (4)

Apoptosis (3)

Autophagy (3)

Bacterial (3)

Calcium Channel (1)

Chloride Channel (3)

Endogenous Metabolite (1)

GHSR (1)

GLUT (1)

Guanylate Cyclase (7)

Interleukin Related (3)

Isotope-Labeled Compounds (1)

mAChR (2)

Motilin Receptor (1)

Opioid Receptor (8)

SARS-CoV (2)

SGLT (2)

TNF Receptor (3)

TRP Channel (1)

By Research Areas:

Cancer (14)

Cardiovascular Disease (1)

Endocrinology (3)

Infection (2)

Inflammation/Immunology (8)

Metabolic Disease (21)

Neurological Disease (18)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N7104

Lactitol D-Lactitol	Bacterial	Endocrinology
Lactitol (D-Lactitol), a nonabsorbable disaccharide, has the potential for constipation research .

HY-A0118A

Naloxegol oxalate 2 Publications Verification NKTR-118 oxalate; AZ-13337019 oxalate	Opioid Receptor	Neurological Disease Cancer
Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-117749

Bisoxatin acetate WY 8138; DB09219 acetate	Others	Metabolic Disease
Bisoxatin (WY 8138; DB09219) acetate is a laxative agent. Bisoxatin acetate is a stimulant for intestinal peristalsis and has the potential for the research of constipation disorder .

HY-N7104R

Lactitol (Standard)	Bacterial	Endocrinology
Lactitol (Standard) is the analytical standard of Lactitol. This product is intended for research and analytical applications. Lactitol (D-Lactitol), a nonabsorbable disaccharide, has the potential for constipation research .

HY-B0680

Lubiprostone (hemiketal) RU-0211 (hemiketal); SPI-0211 (hemiketal)	Chloride Channel	Others Cancer
Lubiprostone (hemiketal) (RU-0211 (hemiketal)) is a selective chloride channel 2 (CLCN2) activator. Lubiprostone (hemiketal) is used to treat chronic idiopathic constipation and opioid-induced constipation by activating CLCN2 channels to increase chloride ion secretion in the intestine, thereby increasing intestinal fluid secretion and enhancing intestinal peristalsis. Lubiprostone (hemiketal) can be used in the study of chronic constipation and cancer .

HY-100243

(+)-Norcisapride Ticalopride	5-HT Receptor	Neurological Disease
(+)-Norcisapride (Ticalopride) is a potent 5-HT4 agonist and a 5-HT3 antagonist. (+)-Norcisapride has activity in animals models of constipation .

HY-A0118

Naloxegol NKTR-118; AZ-13337019	Opioid Receptor	Neurological Disease Cancer
Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-128361

SLC26A3-IN-3	GLUT	Inflammation/Immunology
SLC26A3-IN-3 (compound 4az) is a SLC26A3 inhibitor (IC₅₀: 40 nM). SLC26A3-IN-3 can be used for research of constipation, cystic fibrosis .

HY-121068

Bisoxatin	Angiotensin-converting Enzyme (ACE) SARS-CoV	Infection
Bisoxatin is a laxative drug used for constipation. Bisoxatin binds substantially at the S-protein-ACE2 interface. Bisoxatin has the potential for inhibiting SARS-CoV-2 entry into the host research .

HY-144606

Mu opioid receptor antagonist 1	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 1 (compound 19) is a selective and orally active μ opioid receptor (MOR) ligand with an K_i value of 0.58 nM and an EC₅₀ of 1.15 nM. Orally administrating with Mu opioid receptor antagonist 1 increases intestinal motility during morphine-induced constipation. Mu opioid receptor antagonist 1 can be used for researching opioid-induced constipation (OIC) .

HY-144401

DS-3801b	Motilin Receptor	Metabolic Disease
DS-3801b is a potent and non-macrolide agonist of GPR38. DS-3801b is expected to be novel gastrointestinal prokinetic agents for the research of functional gastrointestinal disorders such as gastroparesis and chronic constipation .

HY-121068R

Bisoxatin (Standard)	Angiotensin-converting Enzyme (ACE) SARS-CoV	Infection
Bisoxatin (Standard) is the analytical standard of Bisoxatin. This product is intended for research and analytical applications. Bisoxatin is a laxative drug used for constipation. Bisoxatin binds substantially at the S-protein-ACE2 interface. Bisoxatin has the potential for inhibiting SARS-CoV-2 entry into the host research .

HY-B0326

Alibendol	Others	Endocrinology
Alibendol can be taken orally. It has anti-spasmodic properties and promotes bile secretion, making it useful for research on digestive system issues like indigestion, nausea, vomiting, and constipation .

HY-19627

Naldemedine S-297995	Opioid Receptor	Neurological Disease Metabolic Disease
Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC₅₀=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine is predicted to bind to 3CL ^pro encoded by SARS-CoV2 genome .

HY-19627A

Naldemedine tosylate S-297995 tosylate	Opioid Receptor	Neurological Disease Metabolic Disease
Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine tosylate shows potent binding affinities (K_i=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC₅₀=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine tosylate is predicted to bind to 3CL ^pro encoded by SARS-CoV2 genome .

HY-15790A

Elobixibat hydrate A 3309 hydrate; AZD 7806 hydrate	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Elobixibat hydrate is a potent ileal bile acid transporter (IBAT) inhibitor, with IC₅₀ values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT. Elobixibat hydrate can be used for chronic idiopathic constipation (CIC) research .

HY-17638

Mizagliflozin 3 Publications Verification DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base	SGLT	Metabolic Disease
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a K_i of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .

HY-108741A

Plecanatide acetate	Guanylate Cyclase	Inflammation/Immunology Cancer
Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis .

HY-111232

GSK894281	GHSR	Metabolic Disease
GSK894281 is an orally active and highly potent ghrelin receptor full agonist with a pEC₅₀ of <4.9 at the human motilin receptor. GSK894281 effectively enters the CNS. GSK894281 has the potential for constipation or to assist in emptying the colon prior to colonoscopy or colon surgery research .

HY-167902

YM-31636 free base	5-HT Receptor	Metabolic Disease
YM-31636 (free base) is an orally active, potent and selective 5-HT₃ receptor agonist with a pK_i value of 9.67. YM-31636 (free base) induces contraction of isolated guinea pig distal colon. YM-31636 (free base) induces tachycardia with the relative intrinsic activity of approximately 0.23 in isolated guinea pig right atrium. YM-31636 (free base) is promising for research of constipation .

HY-17584

Linaclotide 2 Publications Verification	Guanylate Cyclase	Cancer
Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

HY-17584A

Linaclotide acetate	Guanylate Cyclase	Cancer
Linaclotide acetate is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

HY-14151

Prucalopride 2 Publications Verification	5-HT Receptor Apoptosis Autophagy	Neurological Disease Cancer
Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pK_is of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .

HY-14151R

Prucalopride (Standard)	5-HT Receptor Apoptosis Autophagy	Neurological Disease Cancer
Prucalopride (Standard) is the analytical standard of Prucalopride. This product is intended for research and analytical applications. Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pK_is of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .

HY-B0679S

Lubiprostone-d7 RU-0211-d₇; SPI-0211-d₇	Chloride Channel	Metabolic Disease
Lubiprostone-d₇ (RU-0211-d7) is the deuterium labeled Lubiprostone. Lubiprostone (RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation[1][2].

HY-15790H

(S)-Elobixibat (S)-A 3309; (S)-AZD 7806	Apical Sodium-Dependent Bile Acid Transporter TNF Receptor Interleukin Related	Metabolic Disease Inflammation/Immunology
(S)-Elobixibat is the S enantiomer of Elobixibat (HY-15790). (S)-Elobixibat is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor. (S)-Elobixibat decreases LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. (S)-Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors .

HY-17584R

Linaclotide (Standard)	Guanylate Cyclase	Cancer
Linaclotide (Standard) is the analytical standard of Linaclotide. This product is intended for research and analytical applications. Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

HY-15790

Elobixibat A 3309; AZD 7806	Apical Sodium-Dependent Bile Acid Transporter Interleukin Related TNF Receptor	Metabolic Disease Inflammation/Immunology Cancer
Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC₅₀ value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors .

HY-B1172

Lactulose 4-O-β-D-Galactopyranosyl-D-fructose	Endogenous Metabolite Bacterial	Others Cancer
Lactulose (4-O-β-D-Galactopyranosyl-D-fructose) is a poorly absorbed sugar that can be used to study constipation and hepatic encephalopathy. The drug generally begins to take effect 8 to 12 hours after administration, but it may take two days to improve constipation.

HY-B0679

Lubiprostone 1 Publications Verification RU-0211; SPI-0211	Chloride Channel	Metabolic Disease
Lubiprostone (SPI-0211; RU0211) is a gastrointestinal preparation that can act on chronic constipation.

HY-A0118AS

Naloxegol-d5 oxalate	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease
Naloxegol-d₅ (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation[1][2].

HY-106018A

Mitemcinal fumarate GM 611 fumarate	Others	Others
Mitemcinal fumarate is an oral motilium agonist. Studies in rabbits and dogs have shown that it can promote defecation without causing severe diarrhea, increase stool weight without increasing water content in the rabbit constipation model, and reduce the time to first defecation in dogs. Mitemcinal fumarate may be a constipation suppressant due to its early onset and short duration of action.

HY-106018

Mitemcinal GM 611	Others	Others
Mitemcinal (GM 611) is an oral motilium agonist. Studies in rabbits and dogs have shown that it can promote defecation without causing severe diarrhea, increase stool weight without increasing water content in the rabbit constipation model, and reduce the time to first defecation in dogs. Mitemcinal may be a constipation suppressant due to its early onset and short duration of action. .

HY-14152

Prucalopride hydrochloride	5-HT Receptor	Cancer
Prucalopride hydrochloride is an orally active, selective and specific 5-HT4 receptor agonist (high affinity), with pK_is of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride hydrochloride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride hydrochloride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride hydrochloride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .

HY-167687

(RS)-Minesapride	Others	Neurological Disease
(RS)-Minesapride is a serotonin receptor agonist, exhibiting potential therapeutic activity for patients with irritable bowel syndrome with predominant constipation (IBS-C).

HY-P3282

MM 419447	Guanylate Cyclase	Metabolic Disease
MM 419447, a linaclotide metabolite, is a guanylate cyclase-C agonist. MM 419447 has the potential for the research of the irritable bowel syndrome with constipation (IBS-C) .

HY-16765

Axelopran TD-1211	Opioid Receptor	Neurological Disease
Axelopran (TD-1211) is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.

HY-16765A

Axelopran sulfate TD-1211 sulfate	Opioid Receptor	Neurological Disease
Axelopran sulfate is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.

HY-101907

ASP7663 1 Publications Verification	TRP Channel	Neurological Disease
ASP7663 is an orally active and selective TRPA1 agonist. ASP7663 exerts both anti-constipation and anti-abdominal pain actions .

HY-133860

Chrysoobtusin	Others	Others
Chrysoobtusin is an anthraquinone derivative isolated from Semen Cassiae. Semen Cassiae has long been used to protect liver, brighten eyes, and relieve constipation .

HY-B2134

Casanthranol	Others	Metabolic Disease
Casanthranol is a concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.) and used as a laxative in constipation and various medical conditions, stimulant laxative Casanthranol encourages bowel movements by acting on the intestinal wall to increase muscle contractions .

HY-14147

Renzapride BRL 24924	5-HT Receptor	Metabolic Disease
Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT₄ receptor agonist with a K_i value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist . Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study .

HY-10457A

Velusetrag hydrochloride TD-5108 hydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
Velusetrag (TD-5108) hydrochloride is an orally active, potent and selective agonist of serotonin 5-HT₄ receptor (5-HT₄R), with a pK_i of 7.7. Velusetrag hydrochloride exhibits no affinity (K_i>10 μM) for 5-HT_2A and 5-HT_2B receptors. Velusetrag hydrochloride can be used for the research of gastrointestinal diseases and Parkinson's disease .

HY-10457

Velusetrag TD-5108	5-HT Receptor	Neurological Disease Metabolic Disease
Velusetrag (TD-5108) is an orally active, potent and selective agonist of serotonin 5-HT₄ receptor (5-HT4R), with a pK_i of 7.7. Velusetrag exhibits no affinity (K_i>10 μM) for 5-HT_2A and 5-HT_2B receptors. Velusetrag can be used for the research of gastrointestinal diseases and Parkinson's disease .

HY-121826

Naronapride ATI-7505	5-HT Receptor	Metabolic Disease Inflammation/Immunology
Naronapride (ATI-7505) is a potent prokinetic 5-HT₄ receptor agonist. Naronapride can be used for gastrointestinal diseases research .

HY-14147A

(S)-Renzapride (S)-BRL 24924	5-HT Receptor	Metabolic Disease
(S)-Renzapride ((S)-BRL 24924) is the isomer of HY-14147 Renzapride. Renzapride is a 5-HT₄ receptor agonist with a K_i value of 115 nM. Renzapride also is a 5HT2b and 5HT3 receptor antagonist. Renzapride can be used for constipation predominant irritable bowel syndrome (C-IBS) study .

HY-109065

Minesapride	5-HT Receptor	Others
Minesapride is a partial agonist with a highly selective serotonin 4 (5-HT4) receptor. Minesapride enhances gastrointestinal peristalsis and colon transport by activating the 5-HT4 receptor. Minesapride increases bowel movements and suppresses visceral allergic reactions. Minesapride can be used in the study of constipation-type irritable bowel syndrome (IBS-C) .

HY-17638A

Mizagliflozin (sebacate) DSP-3235 (sebacate); KGA-3235 (sebacate); GSK-1614235 (sebacate)	SGLT	Neurological Disease
Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving vascular cognitive impairment caused by small vessel disease. Mizagliflozin sebacate improves blood flow and reverses vascular cognitive impairment by inhibiting neuronal SGLT1 activity. Mizagliflozin sebacate also showed the ability to increase the survival rate of IL-1β-treated PC12HS cells. Mizagliflozin sebacate promotes improvements in spatial learning and memory caused by small vessel disease in mouse models .

HY-B1132

Clidinium bromide Ro 2-3773	mAChR	Neurological Disease
Clidinium bromide is a quaternary amine antimuscarinic agent. Clidinium bromide may help symptoms of cramping and abdominal/stomach pain by decreasing stomach acid, and slowing the intestines in vivo .

HY-108741

Plecanatide	Guanylate Cyclase	Inflammation/Immunology Cancer
Plecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis .

Cat. No.	Product Name	Target	Research Area